Bessemer Group Inc. Sells 15,143 Shares of Axon Enterprise, Inc (NASDAQ:AXON)

Bessemer Group Inc. lessened its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 5.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 257,292 shares of the biotechnology company's stock after selling 15,143 shares during the period. Bessemer Group Inc. owned 0.34% of Axon Enterprise worth $135,324,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in AXON. Pinion Investment Advisors LLC boosted its position in Axon Enterprise by 3.0% during the 1st quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company's stock worth $341,000 after acquiring an additional 19 shares during the last quarter. Kentucky Retirement Systems lifted its position in shares of Axon Enterprise by 0.4% in the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company's stock worth $2,605,000 after purchasing an additional 19 shares in the last quarter. Beacon Pointe Advisors LLC boosted its holdings in Axon Enterprise by 2.6% during the fourth quarter. Beacon Pointe Advisors LLC now owns 864 shares of the biotechnology company's stock worth $513,000 after purchasing an additional 22 shares during the last quarter. Fielder Capital Group LLC grew its position in Axon Enterprise by 2.2% in the fourth quarter. Fielder Capital Group LLC now owns 1,176 shares of the biotechnology company's stock valued at $699,000 after purchasing an additional 25 shares in the last quarter. Finally, Interchange Capital Partners LLC increased its stake in Axon Enterprise by 1.9% in the 4th quarter. Interchange Capital Partners LLC now owns 1,310 shares of the biotechnology company's stock valued at $779,000 after buying an additional 25 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Axon Enterprise Trading Up 2.4%

NASDAQ AXON traded up $18.88 during trading hours on Thursday, reaching $803.95. The company's stock had a trading volume of 484,248 shares, compared to its average volume of 543,030. The firm has a fifty day simple moving average of $704.90 and a 200-day simple moving average of $628.19. The stock has a market cap of $62.59 billion, a P/E ratio of 481.64, a P/E/G ratio of 90.37 and a beta of 1.29. Axon Enterprise, Inc has a 52 week low of $279.02 and a 52 week high of $806.64. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. Axon Enterprise's revenue was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.15 earnings per share. Equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Needham & Company LLC raised their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Barclays raised their price target on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Bank of America upped their price objective on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. The Goldman Sachs Group raised their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Finally, Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $699.55.

Insider Transactions at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the transaction, the chief executive officer now directly owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. The trade was a 0.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Garnreiter sold 87 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $760.00, for a total transaction of $66,120.00. Following the sale, the director now directly owns 24,653 shares of the company's stock, valued at approximately $18,736,280. This trade represents a 0.35% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,642 shares of company stock worth $30,500,428. Company insiders own 4.40% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.